MRI screening for breast cancer in women with familial or genetic predisposition: Design of the Dutch National Study (MRISC)

被引：37

作者：

Kriege M. ^{[1
]}

Brekelmans C.T.M. ^{[1
]}

Boetes C. ^{[2
]}

Rutgers E.J.T. ^{[3
]}

Oosterwijk J.C. ^{[4
]}

Tollenaar R.A.E.M. ^{[5
]}

Manoliu R.A. ^{[6
]}

Holland R. ^{[7
]}

De Koning H.J. ^{[8
]}

Klijn J.G.M. ^{[1
]}

机构：

[1] Rotterdam Family Cancer Clinic, University Medical Centre Rotterdam, Daniel den Hoed Cancer Centre, 3075 EA Rotterdam

[2] Department of Radiology, University Medical Centre Nijmegen, Nijmegen

[3] Department of Surgery, Netherlands Cancer Institute, Amsterdam

[4] Department of Clinical Genetics, University Hospital Groningen, Groningen

[5] Department of Surgery, Leiden University Medical Centre, Leiden

[6] Department of Radiology, VU University Medical Centre, Amsterdam

[7] Department of Pathology, University Medical Centre Nijmegen, Nijmegen

[8] Department of Public Health, University Medical Centre Rotterdam, Rotterdam

来源：

Familial Cancer | 2001年 / 1卷 / 3-4期

关键词：

BRCA1/2; Breast cancer; High risk; Mammography; MRI; Screening;

D O I：

10.1023/A:1021135809870

中图分类号：

学科分类号：

摘要：

Mammography screening of women aged 50-70 years for breast cancer has proven to be effective in reducing breast cancer mortality. There is no consensus about the value of breast cancer screening in women aged 40-49 years. Five to ten per cent of all breast cancers are hereditary. One of the options to reduce the risk of breast cancer mortality for women with a familial or genetic predisposition is intensive surveillance. However, the effectiveness of mammography screening for breast cancer in these women, who are mainly younger than 50 years, is unproven. Magnetic Resonance Imaging (MRI) might increase the effectiveness of screening in women with a familial or genetic predisposition. This paper describes the design of the Dutch national study for MRI screening in women with a familial or genetic predisposition. The aims of this study are to investigate: the value of regular surveillance in women with a familial or genetic predisposition for breast cancer, the efficacy of MRI as compared to mammography, cost-effectiveness of regular screening and quality of life during surveillance. Included are women with a lifetime risk of familial breast cancer of 15% or more or BRCA1/2 mutation carriers, who visit one of the Dutch family cancer clinics. The aim is to include 2500 women. The study started on 1 November 1999. On 1 January 2002, more than 1700 women, including 210 proven carriers of a BRCA1 or BRCA2 mutation, were included in the study.

引用

页码：163 / 168

页数：5

共 35 条

[1]

Visser O., Coebergh J.W.W., Schouten L.J., Et al., Incidence of Cancer in The Netherlands 1996, (2000)

[2]

Coebergh J.W.W., Van der Heijden L.H., Jansen-Heijnen M.L.G., Cancer Incidence and Survival in the Southeast of The Netherlands 1955-1994, (1995)

[3]

Fletcher S.W., Black W., Harris R., Et al., Report of the international workshop on screening for breast cancer, J Nat Cancer Inst, 85, pp. 1644-1656, (1993)

[4]

Tabar L., Fagerberg G., Chen H.-H., Et al., Efficacy of breast cancer screening by age. New results from the Swedish two-country trial, Cancer, 75, pp. 2507-2517, (1995)

[5]

Olsen O., Gotzsche P.C., Cochrane review on screening for breast cancer with mammography, Lancet, 358, pp. 1340-1342, (2001)

[6]

Nystrom L., Andersson I., Bjurstam N., Et al., Long-term effects of mammography screening: Updated overview of the Swedish randomised trials, Lancet, 359, pp. 909-919, (2002)

[7]

De Koning H.J., Boer R., Warmerdam P.G., Et al., Quantitative interpretation of age-specific mortality reductions from the swedish breast cancer-screening trials, J Nat Cancer Inst, 87, pp. 1217-1223, (1995)

[8]

Report of the Organizing Committee and Collaborators, Falun Meeting, Falun, Sweden (21 and 22 March, 1996). Breast-cancer screening with mammography in women aged 40-49 years, Int J Cancer, 68, pp. 693-699, (1996)

[9]

Elmore J.G., Barton M.B., Moceri V.M., Et al., Ten year risk of false positive screening mammograms and clinical breast examinations, New Eng J Med, 338, pp. 1089-1096, (1998)

[10]

Verhoog L.C., Van den Ouweland A.M.W., Berns E., Et al., Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families, Eur J Cancer, 37, pp. 2082-2090, (2001)

← 1 2 3 4 →